Ask AI
ProCE Banner Activity

Expert Perspectives on Novel and Emerging HER2-Directed and TROP-2‒Targeted ADCs for Advanced Breast Cancer

Clinical Thought

In this engaging “Xtorial,” an expert interacts with healthcare professionals on the role of novel antibody‒drug conjugates in the management of patients with advanced breast cancer.

Released: May 02, 2024

Expiration: May 01, 2025

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Kevin Kalinsky, MD, MS, FASCO

Professor of Medicine
Louisa and Rand Glenn Family Chair in Breast Cancer Research
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Gilead, Puma Biotechnology, Seattle Genetics.